A Phase 1/2 interventional study of Deanxit and Prozac in Syndrome X, sponsored by RenJi Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-03-04.
Sponsored by RenJi Hospital · Phase 1/2, Interventional, and Treatment
A comparative study is conducted on the patients with suspected coronary artery disease (CAD). The patient will undergo coronary angiography after a somatic symptom scale (SSS) survey is carried out combining with Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder 7-items (GAD-7). Patient is then treated according to the checklist score and coronary angiography result. The efficacy, sensitivity and specificity of the SSS checklist will be evaluated during following up.
The presentation of physical complaints such as chest discomfort suggestive of suspicious coronary artery disease (CAD) but remain unexplained after negative finding from coronary angiography represents one of the most frustrating and puzzling problems in clinical medicine.A comparative study is conducted on the patients with suspected coronary artery disease. A somatic symptom scale (SSS) survey is carried out combining with Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder 7-items (GAD-7). Patient is treated according to the checklist score and coronary angiography result. Three surveys will be re-conducted 2 weeks after treatment. The sensitivity and specificity of the SSS checklist will be evaluated during following up.
126 studies on the registry are indexed under Microvascular Angina; 37 are open to participants now.
This study's planned enrollment of 200 is above the median of 70 across 80 interventional studies indexed under Microvascular Angina.
Browse Microvascular Angina studies →RenJi Hospital is the lead sponsor of 550 studies on the registry; 248 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with the coronary artery disease and with the somatization symptom, the investigators treat the patients according to the guideline for coronary artery disease and anti-somatic agents (Deanxit, Prozac according to the somatization type)
Drug: Deanxit · Drug: Prozac · Procedure: coronary artery disease treatment
Only somatic symptom is presented, anti-somatic agents is prescribed (Deanxit, Prozac according to the somatization type)
Drug: Deanxit · Drug: Prozac
Have neither coronary artery disease nor somatic symptom, continue follow-up.
Patient with the coronary artery disease, without the somatization symptom, the investigators treat the patients according to coronary artery disease treatment guideline including coronary artery stent implantation,medication according to the severity of stenosis of the coronary arteries.
Procedure: coronary artery disease treatment
we use Deanxit for the patient with anxiety
Also known as: Deanxit as anti-anxiety treatment
we use Prozac for the patient with depression
Also known as: Prozac as anti-depression treatment
including medication, coronary artery stent implantation according to the severity of stenosis of the coronary arteries
Also known as: re-vascularization
The efficacy of somatization symptom score
observe the efficacy by the score of somatic symptom scale (SSS), Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-items (GAD-7)
Time frame: 2 weeks after the first visit
scale chest discomfort
observe if the chest discomfort no change, alleviate or disappear
Time frame: 2 weeks after the first visit
The efficacy of Patient Health Questionnaire
observe the efficacy by the score of Patient Health Questionnaire (PHQ-9)
Time frame: 2 weeks after the first visit
The efficacy of Generalized Anxiety Disorder 7-items
observe the efficacy by the score of Generalized Anxiety Disorder 7-items (GAD-7)
Time frame: 2 weeks after the first visit
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Dec 2015, a primary completion of Dec 2020 and a completion of Dec 2021. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluoxetine